Zenas BioPharma, Inc.

ZBIO · Nasdaq · SIC 2834: Pharmaceutical Preparations
31
SEC Filings

Business Summary

PART I Overview We are a clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need. With the evolving understanding 6 Table of Contents of the pathogenesis of autoimmune diseases, along with the expansion of promising immunology-based pharmacologic targets, we are building an I&I focused biopharmaceutical company. Our core business strategy combines disciplined product can...

Next Earnings

Q2 FY2026 — expected 2026-09-09

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionZBIOdiscussed_in_filing Cybersecurity
topic_mentionZBIOdiscussed_in_filing Trusted Computing
topic_mentionZBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionZBIOdiscussed_in_filing Capital Expenditure
topic_mentionZBIOdiscussed_in_filing Regulation
topic_mentionZBIOdiscussed_in_filing Healthcare & Bio
topic_mentionZBIOdiscussed_in_filing Sovereign & Government
topic_mentionZBIOdiscussed_in_filing Cybersecurity
topic_mentionZBIOdiscussed_in_filing Trusted Computing
topic_mentionZBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionZBIOdiscussed_in_filing Capital Expenditure
topic_mentionZBIOdiscussed_in_filing Regulation
topic_mentionZBIOdiscussed_in_filing Healthcare & Bio
topic_mentionZBIOdiscussed_in_filing Sovereign & Government
topic_mentionZBIOdiscussed_in_filing Cybersecurity
topic_mentionZBIOdiscussed_in_filing Trusted Computing
topic_mentionZBIOdiscussed_in_filing Blockchain & Crypto
topic_mentionZBIOdiscussed_in_filing Capital Expenditure
topic_mentionZBIOdiscussed_in_filing Regulation
topic_mentionZBIOdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-162025-12-310001104659-26-027964EDGAR131K words
2025-03-112024-12-310001558370-25-002631EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001104659-25-109753EDGAR73K words
2025-08-122025-06-300001558370-25-011147EDGAR—
2025-05-152025-03-310001558370-25-007803EDGAR—
2024-11-122024-09-300001558370-24-015162EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001104659-26-037821EDGAR42K words
2026-03-160001104659-26-027961EDGAR—
2026-02-130001104659-26-015314EDGAR—
2026-01-050001104659-26-000402EDGAR—
2025-12-150001104659-25-121182EDGAR—
2025-11-120001104659-25-109737EDGAR—
2025-10-270001104659-25-102317EDGAR—
2025-10-080001104659-25-097663EDGAR—
2025-09-020001104659-25-085982EDGAR—
2025-08-120001104659-25-076464EDGAR—

31 total filings indexed. 15 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001953926
TickerZBIO
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: b420ccac77cb5e11002f08771f9b89f534e1631303830e6276cc6b61d295300f
parent: c3cbda1eb42b20c2b5461070194f581a7d5247f7d56c8eb3deece60035cdc7c5
content hash: 51b1dd089422e4be96011872e5b6ab76c384257b9e5eeff958ddedd7d599ad92
signed: 2026-04-13T04:48:21.840Z
sources: 6 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf